119 related articles for article (PubMed ID: 1111465)
1. Sequential therapy compared with combination therapy in multiple myeloma.
Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
[TBL] [Abstract][Full Text] [Related]
2. Remission maintenance therapy for multiple myeloma.
Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
[TBL] [Abstract][Full Text] [Related]
3. Treatment of plasma cell myeloma with cytotoxic agents.
Bergsagel DE; Pruzanski W
Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
[TBL] [Abstract][Full Text] [Related]
4. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
5. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
6. Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein.
Solomon A
J Clin Invest; 1978 Jan; 61(1):97-108. PubMed ID: 618916
[TBL] [Abstract][Full Text] [Related]
7. [Cyclical chemotherapy of myeloma with cell synchronization: therapeutic trial. Apropos of 13 cases].
Roux H; D'Omezon Y; Lagier C; Thouveny F; Recordier AM
Rev Rhum Mal Osteoartic; 1976 Feb; 43(2):113-6. PubMed ID: 772787
[TBL] [Abstract][Full Text] [Related]
8. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
9. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
10. [Results of the treatment of myeloma with a vincristine-melphalan combination].
Roux H; d'Omezon Y; Gaborit P; Eisinger F; Serratrice G
Rev Rhum Mal Osteoartic; 1979; 46(7-9):443-8. PubMed ID: 315613
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Kahler's disease].
Foa J; Carcassonne Y
Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
[No Abstract] [Full Text] [Related]
13. Multiple myeloma and acute leukemia associated with alkylating agents.
Kyle RA; Pierre RV; Bayrd ED
Arch Intern Med; 1975 Jan; 135(1):185-92. PubMed ID: 1053891
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
15. [Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision].
Johnsen HE; Bergmann OJ; Boesen AM; Pedersen BB; Ellegaard J; Bastrup-Madsen P
Ugeskr Laeger; 1989 Mar; 151(13):816-21. PubMed ID: 2718264
[TBL] [Abstract][Full Text] [Related]
16. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
[TBL] [Abstract][Full Text] [Related]
17. Correlation of abnormal immunoglobulin with clinical features of myeloma.
Arch Intern Med; 1975 Jan; 135(1):46-52. PubMed ID: 1111470
[TBL] [Abstract][Full Text] [Related]
18. Clinical classification of plasma cell myeloma.
Conklin R; Alexanian R
Arch Intern Med; 1975 Jan; 135(1):139-43. PubMed ID: 1111462
[TBL] [Abstract][Full Text] [Related]
19. [Progress in the treatment of multiple myeloma].
Wada M; Mizoguchi H
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
